Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, ...

PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH ...

For adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, long-term treatment with tofersen (Qalsody, Biogen) was associated with slowed ...

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...

Please provide your email address to receive an email when new articles are posted on . Survival rates of those on riluzole were similar to rates of patients with other neuromuscular conditions. The ...

The MarketWatch News Department was not involved in the creation of this content. Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an ...

With the help of artificial intelligence, a coalition of Bay Area institutions identified 18 FDA-approved drugs that could improve the lives of those suffering from amyotrophic lateral sclerosis, ...

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data ...

During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases. Now new research published at the ATS 2025 ...

CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...